All articles by Manasi Vaidya

Manasi Vaidya


Manasi Vaidya is the lead editor for Pharmaceutical Technology where she covers the healthcare space. She writes features that look at the research, regulation and reimbursement of drugs with a focus on topics at the intersection of business and science. She is based in Brooklyn and an alum of New York University’s Science, Health and Environmental Reporting program.

Magazine: Pharma’s path to Net Zero: Targeting Scope 3 emissions

In this issue: Pharma’s efforts to curb Scope 3 emissions, understanding European Pharmaceutical legislation, predicting the future of cell and gene therapy manufacturing, and looking back at the pharma industry’s performance in 2023.

Magazine: What’s in a name

In this issue: Fixing drug nomenclature to avoid confusing names, gene therapies for sickle cell disease, childproof packaging for drugs, and UK pharma manufacturing gears up for a shake up in 2024

Pharmaceutical Technology’s most-read stories of 2023

Our most popular stories of the year involve CRISPR therapies, generative AI, obesity drugs entering prime time, and changes in the Covid-19 landscape, signaling the biggest trends in the pharmaceutical and biotech industry.

Magazine: Advancing islet transplantation for type 1 diabetes

In this issue: Diabetes researchers oppose the regulation of islet transplantation as a biologic in the US, why haemophilia gene therapies are so expensive, how AI will help with trial recruitment.

How commercial employer plans and coverage matter for orphan drugs

In a two-part column, F. Randy Vogenberg touches upon the key challenges in the employer-based US commercial insurance landscape.

How to connect patients with rare diseases to clinical trials

Experts say a wider diverse pool of patients needs to be given a chance to participate in clinical research to get rare disease drugs faster to market.

Rare disease drug development needs regulatory incentives to grow in 2024

While orphan drug approvals have hit an all-time high, existing incentives need to continue to further support rare disease research.

Signal- HHS/Regeneron Covid-19 deal includes list price clause for affordability

Regeneron is developing an antibody for Covid-19 prevention with the help of US government funding.

Magazine: Digital dilemma in UK’s life sciences job market

In this issue: Digital jobs in UK life sciences, generative AI changes drug discovery, and how robotics is impacting gene therapy manufacturing.

Signal: Nimbus raises $210m to foster drug discovery plans

Nimbus plans to use these funds to aid new drug discovery efforts and plans to continue existing programs in oncology and metabolic disorder.